The Cholesterol Clue

A tiny smudge in a century-old medical paper might be one of the most useful clues we have for Alzheimer’s disease prevention today. We trace that smudge back to 1907, when Alois Alzheimer documented not only plaques and tangles, but also lipid accumulation inside glial cells, a finding the field largely shrugged off for decades. Once you add modern genetics, especially ApoE4 and its role in lipid transport, the idea that cholesterol and brain health are deeply linked stops sounding like a stretch and starts sounding like unfinished science. 

From there, we dig into Tobias Hartman’s 2026 editorial and the clinical data behind it, including a massive 10-year cohort study of nearly 50,000 people. The numbers are easy to mock at first glance: changes like 0.01 or 0.17 on the Clinical Dementia Rating Sum of Boxes (CDRSB). But we walk through the “time saved” method that converts score differences into something families actually feel: months of cognitive function. It is the difference between a statistic and a calendar, and it reframes why modest effects can still matter in neurodegenerative disease. 

Then we wrestle with the catch. Observational data brings confounding. Different statins behave differently. And the most unsettling twist: MRI and cerebrospinal fluid biomarkers like hippocampal atrophy and tau do not significantly improve, even when cognition seems to hold on longer. That tension points toward a bigger possibility: maybe vascular health, endothelial function, and whole-body metabolism help determine how long the brain can cope with underlying pathology. If you want a clear-eyed, nuance-first guide to statins, Alzheimer’s risk, and why combination strategies like the FINGER protocol may be the real future, listen now, subscribe, and share your take with us in a review.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Transcript

The Smudge Everyone Missed

SPEAKER_00 0:00

Imagine looking at uh like a century-old crime scene photo. You know, you were staring at this grainy image trying to figure out what happened, and you realize the most important clue wasn't the smoking gun lying right in the center of the room.

SPEAKER_01 0:12

Aaron Powell Right. It's usually something completely unexpected.

SPEAKER_00 0:16

Exactly. It was just the smudge on the window that everyone completely ignored because they were, I mean, they were too distracted by the obvious evidence.

SPEAKER_01 0:23

Aaron Powell Yeah, that happens a lot in science, actually.

SPEAKER_00 0:25

Aaron Powell It really does. And if you've ever wondered if fixing your whole body could actually, you know, save your mind, well, this deep diet is entirely for you. Because back in 1907, the doctor who first discovered Alzheimer's left us exactly that kind of overlooked clue.

SPEAKER_01 0:43

Aaron Powell It is just a phenomenal example of how scientific progress isn't uh it's not always a straight line. We often have to dig through these historical archives to make sense of the latest clinical data. Yeah. Especially when we are dealing with a disease that has frankly outsmarted us for this long.

SPEAKER_00 1:00

And the source we are analyzing today forces us to do exactly that. We are

Why Cholesterol Matters For Dementia

SPEAKER_00 1:05

pulling from an editorial published in the 2026 Journal of Prevention of Alzheimer's Disease.

SPEAKER_01 1:10

Written by Tobias Hartman, right?

SPEAKER_00 1:11

Yes, Tobias Hartman. It is titled Lipid Lowering Regimens in Alzheimer's Disease Dementia, Small Effects with Potential Long-Terfit?

SPEAKER_01 1:19

Quite a mouthful.

SPEAKER_00 1:20

It is, yeah. But the mission for this deep dive is to basically synthesize this dense medical text and answer a really specific critical question. Can common heart medications, uh specifically drugs that lower your cholesterol, actually slow down the cognitive decline of Alzheimer's?

SPEAKER_01 1:39

Which is a huge question.

SPEAKER_00 1:41

Huge. Okay, let's unpack this. Because to understand why modern neurologists are suddenly so obsessed with cholesterol drugs, we have to travel back to the very first time Alzheimer's was ever officially characterized.

SPEAKER_01 1:51

Yeah, we have to go all the way back to Alice Alzheimer's original 1907 paper. Right. When he first examined the brain tissue of a patient who had died from this, well, this mysterious severe dementia, he identified three distinct molecular hallmarks under his microscope.

SPEAKER_00 2:05

Aaron Ross Powell Three of them. And we usually only hear about two.

SPEAKER_01 2:08

Exactly. The first two hallmarks became the cornerstone of a century of research. We are talking about neurofibrillary tangles and amyloid plaques.

SPEAKER_00 2:18

The famous plaques and tangles.

SPEAKER_01 2:20

Right. Those two structural anomalies have just dominated billions of dollars in funding. But Alzheimer's actually documented a third hallmark in that very same paper. He called them uh glial adipose sacches.

SPEAKER_00 2:34

Okay, I have read a lot about plaques and tangles over the years, but glial adipose sacules is definitely a new one for me.

SPEAKER_01 2:41

It sounds very archaic.

SPEAKER_00 2:42

It really does. Break down that turn-of-the-century terminology for it.

SPEAKER_01 2:45

Sure. So in modern biological terms, he was describing intracellular lipid accumulation.

SPEAKER_00 2:50

Aaron Ross Powell Meaning fat inside the cells.

SPEAKER_01 2:52

Basically, yeah. He saw these little droplets of fat building up inside the brain's support cells, which are the glia. Wow. But for the better part of a century, that observation was totally sidelined. I mean, the scientific community looked at those fat droplets and assumed they were just a byproduct of dying brain tissue. Trevor Burrus, Jr.

SPEAKER_00 3:08

Like just trash left over from the damage.

SPEAKER_01 3:10

Aaron Ross Powell Exactly. Kind of like debris left over after a building collapses, you know. The tangles and the plaques were viewed as the main event.

SPEAKER_00 3:18

Okay.

The Third Hallmark Alzheimer Noted

SPEAKER_01 3:19

And it wasn't until about 30 years ago that the journal Science published this really provocative article titled Bad for the Heart, Bad for the Mind, which finally challenged that whole assumption.

SPEAKER_00 3:29

Aaron Powell And that article started connecting the dots between cardiovascular health and brain health, right? Trevor Burrus, Jr.

SPEAKER_01 3:35

It did.

SPEAKER_00 3:35

Because they noticed that statins were doing something unexpected.

SPEAKER_01 3:38

Aaron Powell Yeah. That science article highlighted some early epidemiological data suggesting that statins, which are, you know, cholesterol-lowering drugs, might actually lower amyloid beta in the brain. But more importantly, it coincided with a growing understanding of the genetics of Alzheimer's. We realized around then that the strongest genetic risk factor for late-onset Alzheimer's is a gene variant called ApoE4.

SPEAKER_00 4:05

Aaron Ross Powell, which is something anyone who has taken a commercial DNA test for health risks has probably heard of. Like it pops up all the time.

SPEAKER_01 4:11

Oh, absolutely. It's very well known now.

SPEAKER_00 4:13

Aaron Ross Powell But how does ApoE4 actually connect to those little fat droplets Alzheimer's song?

SPEAKER_01 4:18

Aaron Ross Powell Well, what is remarkable is that ApoE's literal day job in the human body is lipid transport. It is an apolipoprotein. Okay. So its primary function is to physically carry cholesterol and other fats through the bloodstream and the brain.

SPEAKER_00 4:33

Wow. So if the biggest genetic risk factor for the disease is basically a broken cholesterol delivery truck.

SPEAKER_01 4:39

Exactly.

SPEAKER_00 4:40

And Alice Alzheimer saw fat accumulating in the brain cells all the way back in 1907, the connection becomes kind of undeniable.

SPEAKER_01 4:49

It does. It shows the lipid system is fundamentally involved in the pathology.

SPEAKER_00 4:53

So the historical blind spot wasn't just like a miss detail. It was a fundamental misunderstanding of the brain's metabolism. Right. Spent decades staring at the plaques, completely ignoring the fact that the brain's fat transport system was breaking down right in front of us.

SPEAKER_01 5:06

What's fascinating here is how this realization completely shifted the paradigm of modern prevention strategies.

ApoE4 And Broken Lipid Transport

SPEAKER_01 5:12

Also. Well, we finally recognized that systemic factors like elevated midlife cholesterol are major modifiable risk factors for the disease.

SPEAKER_00 5:22

Aaron Powell Modifiable meaning we can actually do something about them.

SPEAKER_01 5:25

Exactly. We stopped looking at the brain as this isolated fortress that just operates independently of the rest of the body. And that brings us to the present day, where researchers are trying to see if we can manipulate that cholesterol system to actually change the course of the dementia.

SPEAKER_00 5:40

Which brings us to the clinical data at the center of the Hartman editorial. Because this isn't just theoretical biology anymore.

SPEAKER_01 5:46

No, not at all.

SPEAKER_00 5:47

Hartman focuses on a massive perspective study by Sternberg and colleagues. And when I say massive, I mean they followed nearly 50,000 participants for 10 years.

SPEAKER_01 5:57

Aaron Powell It is an incredibly robust data set. Sternberg's team wanted to measure the actual impact of lipid lowering regimens on cognitive decline over time. So they tracked participants moving from normal cognition into mild cognitive impairment or MCI, and then subsequently into full dementia.

SPEAKER_00 6:15

Aaron Powell And how do they measure that? Like what's the ruler they use?

SPEAKER_01 6:17

Aaron Powell To quantify that decline, they use something called the CDRSB, which stands for Clinical Dementia Rating Sum of Boxes.

SPEAKER_00 6:25

Sum of boxes.

SPEAKER_01 6:26

Yeah. It is a standard scale neurologist use to score a patient's memory, orientation, judgment, and personal care. The higher the score, the worse the impairment.

SPEAKER_00 6:36

Aaron Powell Okay, and with 50,000 people over a full decade,

The 50,000 Person Statin Signal

SPEAKER_00 6:40

you get the kind of statistical power that can detect even the tiniest fluctuations in human cognition.

SPEAKER_01 6:46

Exactly. You can see the smallest signals.

SPEAKER_00 6:48

Aaron Powell But I have to bring up the actual numbers they found. Because I read this, and for the group converting from normal cognition to mild cognitive impairment, the researchers found a difference of eleven hundredth of a CDRSB point per year compared to non-users.

SPEAKER_01 7:02

That is the reported figure, yes. An annual difference of.01 points.

SPEAKER_00 7:06

Wait, eleven hundredth of a point?

SPEAKER_01 7:08

Yeah.

SPEAKER_00 7:08

Is that even worth putting in a medical journal, let alone discussing here? I mean, a human being's mood on a random Tuesday could probably fluctuate their memory test by more than eleven hundredth of a point. That sounds like a statistical rounding error, not a medical breakthrough.

SPEAKER_01 7:23

Your skepticism is entirely justified, and you know, the editorial actually validates that exact pushback. In a standard clinical setting, eleven hundredth of a point is entirely negligible. Right. A patient and their family would absolutely never notice that kind of difference day to day. But the researchers didn't just stop there. Okay. When they stratified the data and looked at a different subset of patients, the narrative changed pretty significantly. They looked at individuals older than 50 who already had a higher degree of baseline cognitive impairment.

SPEAKER_00 7:52

So people who are already showing real symptoms.

SPEAKER_01 7:55

Yeah, specifically people with a CDRSB score greater than three. For that group, the benefit of the lipid lowering drugs increased to a reduction of 0.17 points annually.

SPEAKER_00 8:05

Okay, well, 0.17 is undeniably larger than 0.01.

SPEAKER_01 8:08

Definitely.

SPEAKER_00 8:09

But let's be honest, to the average listener trying to figure out how to help, say, a parent with dementia, 0.17 still sounds pretty microscopic.

SPEAKER_01 8:17

It does sound small.

SPEAKER_00 8:18

We need to bridge the gap between

Turning CDRSB Points Into Time

SPEAKER_00 8:20

abstract clinical statistics and human reality here.

SPEAKER_01 8:23

Uh-huh.

SPEAKER_00 8:24

Why does the scientific community care so much about a 0.17 annual reduction?

SPEAKER_01 8:29

Because in neurodegenerative diseases, we have to translate these abstract point scores into the one metric that actually matters to patients, which is time.

SPEAKER_00 8:39

Time.

SPEAKER_01 8:40

Yes. The editorial introduces this really brilliant analytical concept called time saved. It references the recent methodological work by researchers Dixon and Hendricks.

SPEAKER_00 8:50

Okay, and what did they do?

SPEAKER_01 8:52

They developed a mathematical model to convert these tiny fractional differences on the CDRSB scale into actual months of life gained.

SPEAKER_00 9:00

How do they actually calculate that though? Yeah. Because time saved sounds great in a brochure, but how does the math actually work in a clinical trial?

SPEAKER_01 9:08

It is based on mapping the trajectory of decline.

SPEAKER_00 9:11

Okay.

SPEAKER_01 9:11

Imagine drawing a downward sloping line that represents how fast the placebo group is losing their cognitive function over a year.

SPEAKER_00 9:17

Aaron Powell Right. So a steady slope downwards.

SPEAKER_01 9:19

Then you plot the treatment group's decline on the exact same graph. Because the treatment group is declining slightly slower, say 0.17 points slower, their line is a bit flatter.

SPEAKER_00 9:29

Uh-huh.

SPEAKER_01 9:30

The time saved is calculated by looking at where the treatment group ended up at the end of the trial, and then tracing horizontally to see how many months earlier the placebo group hit that exact same level of impairment.

SPEAKER_00 9:41

Oh wow. So it is literally measuring the gap in time between when the two groups crossed the exact same threshold of memory loss.

SPEAKER_01 9:48

Precisely. To give you some context for how this looks in practice, Hendrix evaluated the high-profile Alzheimer's drug Donamab.

SPEAKER_00 9:55

Right. That's been in the news a lot.

SPEAKER_01 9:57

It has. In its clinical trials, Donomab showed a CDR SB difference of 0.36 points over 76 weeks. Okay. When they ran that trajectory math, that fractional point difference translated to delaying the disease progression by about 5.2 months.

SPEAKER_00 10:14

That's almost half a year.

SPEAKER_01 10:15

Exactly. Another intervention they looked at, Fortis and Connect, showed a 0.6 point difference over 24 months, which translated to a delay of 10.5 months.

SPEAKER_00 10:25

Here's where it gets really interesting. If we apply that trajectory math to these standard cholesterol drugs, the whole perspective shifts, right?

SPEAKER_01 10:32

It really does. If an older patient with mild impairment is seeing a 0.17 point reduction annually from their lipid lowering regimen, you are looking at a compounding effect over time.

SPEAKER_00 10:43

Aaron Powell I like to think of it like putting loose change in a jar rather than trying to, you know, win the lottery.

SPEAKER_01 10:49

That's a great way to look at it.

SPEAKER_00 10:50

Taking a statin isn't going to cure the disease overnight. But if you are saving a fraction of a point this year and another fraction next year and the year after that, I mean, over a five or ten year period, that compounding interest suddenly buys you real meaningful time.

SPEAKER_01 11:06

Absolutely.

SPEAKER_00 11:07

You are talking about potentially extending a person's ability to recognize their grandchildren or manage their own household by several months.

SPEAKER_01 11:16

If we connect this to the bigger picture, this is exactly why the scientific community is paying so much attention. Yeah. A sustained compounding reduction of 0.17 points annually transforms what looks like a modest statistical blip into a profoundly meaningful clinical outcome. Buying six months of cognitive independence is a triumph in Alzheimer's care.

SPEAKER_00 11:37

It is a massive triumph. But wait, if this compounding math is so incredibly promising, why isn't every neurologist on the planet just aggressively prescribing cholesterol medications specifically for dementia

The Catch With Observational Data

SPEAKER_00 11:50

right now?

SPEAKER_01 11:50

Well, that's the catch.

SPEAKER_00 11:51

Right. What is the catch in the data? Because we cannot give you, the listener, the impression that statins are this flawless biological shield without looking at the study's scientific red flags.

SPEAKER_01 12:02

And the red flags are significant. They largely stem from the nature of observational cohort studies.

SPEAKER_00 12:08

Which is what just was.

SPEAKER_01 12:09

Right. In a controlled clinical trial, you dictate exactly who gets what. But in a cohort study like Sternberg's, you are just observing people out in the wild over a decade.

SPEAKER_00 12:18

You're seeing what happens naturally.

SPEAKER_01 12:19

Exactly. The researchers tried to mimic real-world conditions by keeping the inclusion criteria broad. Basically, it just asks, did you take a lipid lowering drug or not? Okay. But their exclusion criteria created a major blind spot. They specifically excluded anyone receiving anti-diabetic or antihypertensive therapies.

SPEAKER_00 12:37

Wait, what? Which knocks out a huge percentage of the elderly population.

SPEAKER_01 12:41

A massive percentage, yes.

SPEAKER_00 12:43

Why would the researchers do that? Yeah. Why exclude the exact people who are most likely to be taking a heart medication in the first place?

SPEAKER_01 12:49

Aaron Powell They kind of had to exclude them because of something called vascular confounding.

SPEAKER_00 12:54

Vascular confounding.

SPEAKER_01 12:55

Yeah. High blood pressure physically damages the tiny microvessels in the brain, and diabetes severely impairs how the brain processes glucose. Right. Both of those conditions independently accelerate cognitive decline. If the researchers had included patients on blood pressure and diabetes medications, they wouldn't really know if the cognitive scores were changing because of the cholesterol drugs or just because the patient's blood pressure was finally under control. Trevor Burrus, Jr.

SPEAKER_00 13:24

Oh, that makes sense. You wouldn't know which drug was doing the heavy lifting.

SPEAKER_01 13:26

Aaron Powell Exactly. But by excluding them, it severely limits how well these findings actually apply to the general public, where these conditions usually, you know, travel together.

SPEAKER_00 13:36

Aaron Powell So the data is incredibly clean, but arguably disconnected from the messy reality of an average patient's medicine cabinet.

SPEAKER_01 13:45

Aaron Powell That's a fair assessment.

SPEAKER_00 13:46

Aaron Powell And on top of that, the study lumped all lipid-lowering regimens into one big bucket, right? Like they didn't separate the different classes of drugs.

SPEAKER_01 13:56

Aaron Ross Powell That is another major limitation. The vast majority of the drugs taken were statins, but not all statins are identical. Right. Some are lipophilic, meaning they can easily cross the blood-brain barrier and enter the brain tissue directly. While others are hydrophilic, meaning they largely stay in the bloodstream and act strictly on the liver. By pooling them all together, the study obscures which specific biochemical mechanism is actually providing that 0.17 point benefit. Trevor Burrus, Jr.

SPEAKER_00 14:24

That's frustrating.

SPEAKER_01 14:25

Trevor Burrus, Jr. It is. But the most glaring biological mystery of this entire study, and honestly, the reason neurologists remain so cautious is the complete lack of physical biomarker

Biomarkers Stay The Same Anyway

SPEAKER_01 14:35

confirmation.

SPEAKER_00 14:35

Aaron Powell Right. Let's dig into that physical evidence in the brain. What did the MRI scans and the spinal taps actually show in the people taking these drugs?

SPEAKER_01 14:43

Aaron Powell Well, they showed absolutely no significant differences.

SPEAKER_00 14:46

None at all.

SPEAKER_01 14:47

None. First, the researchers looked at heppocampal atrophy, which is the physical shrinkage of the brain's memory center. The brains of the patients on the cholesterol drugs were shrinking at the exact same rate as the patients who weren't. Wow. Second, they looked at cerebrospinal fluid tau concentrations.

SPEAKER_00 15:04

Aaron Ross Powell And Tau is essentially the biological scaffolding of a neuron, right?

SPEAKER_01 15:08

Yeah, think of tau like the railroad ties holding the transport tracks of a brain cell together.

SPEAKER_00 15:14

Okay, good visual.

SPEAKER_01 15:15

In Alzheimer's, those ties disintegrate, the tracks collapse, and they tangle up. That structural collapse was happening just as fast in the statin group. Jeez. And finally, there was no difference in brake staging, which is the method pathologists use to map how far the disease has physically spread outward from the memory center into the rest of the cortex.

SPEAKER_00 15:34

Okay, this is where my brain starts to break a little bit. It is like looking under the hood of a car and seeing that the engine is rusting, the spark plugs are dead, and the transmission is shot at the exact same rate as the car next to it.

SPEAKER_01 15:46

Right.

SPEAKER_00 15:46

But somehow your car is driving an extra 10,000 miles before it breaks down.

SPEAKER_01 15:50

That's a great analogy.

SPEAKER_00 15:52

If the physical brain shrinkage, the tau collapse, and the spreading pathology are all marching along identically, how on earth is the patient's actual real-world memory holding on longer?

SPEAKER_01 16:03

That is the central paradox we are currently grappling with. The absence of changes in those physical biomarkers indicates that the lipid-lowering drugs do not have a disease-modifying effect.

SPEAKER_00 16:14

Meaning they aren't stopping the root cause.

SPEAKER_01 16:16

Exactly. They aren't stopping the core Alzheimer's pathology. What they might be doing, though, is providing a symptom modifying effect through a completely parallel pathway.

SPEAKER_00 16:26

Like what?

SPEAKER_01 16:27

Well, for example, by drastically improving the health of the endothelial cells lining the brain's blood vessels, the drugs might be reducing systemic inflammation, which would allow the brain to function better despite the creeping Alzheimer's pathology. But we do have to acknowledge that observational studies are vulnerable to bias, which can sometimes artificially inflate how effective a treatment looks.

SPEAKER_00 16:49

So, what does this all mean for the listener? We have a drug class that is cheap, safe, and heavily prescribed, which might give you a compounding fractional benefit that buys you precious months of cognitive function. Right. Yet we don't fully understand the biological mechanism, and the drugs don't actually stop the brain from physically shrinking. Where does this leave the future of Alzheimer's treatment?

Combining Statins With Lifestyle Trials

SPEAKER_01 17:11

This raises an important question about our entire philosophy of treating age-related cognitive decline. Because the effects of these lipid-lowering regimens are modest and don't stop the core pathology, we just cannot look at them as a standalone magic bullet.

SPEAKER_00 17:25

Right. There is no single pill.

SPEAKER_01 17:27

No. The future is clearly combinatorial. Hartman's editorial specifically points out that future clinical trials must evaluate statins in combination with things like the finger protocol.

SPEAKER_00 17:37

I'm so glad you brought up the finger protocol. That is the finished geriatric intervention study. Right.

SPEAKER_01 17:42

That's the one.

SPEAKER_00 17:43

It isn't just about taking a pill, it is a highly structured, multidomain approach.

SPEAKER_01 17:47

Exactly. The finger intervention rigorously combines nutritional guidance, intensive physical exercise, targeted cognitive training, and strict monitoring of vascular risk factors all at once.

SPEAKER_00 18:00

It's a whole lifestyle overhaul.

SPEAKER_01 18:01

It is. Hartman suggests that if we layer the modest, compounding benefit of a targeted lipid lowering drug on top of the profound lifestyle resilience built by something like the finger protocol, we might finally outpace the disease.

SPEAKER_00 18:14

That makes a lot of sense.

SPEAKER_01 18:15

But to do that effectively, we urgently need rigorous controlled trials to figure out exactly which specific cholesterol agents cross the blood-brain barrier best and how they interact with Tau and amyloid in a living patient.

SPEAKER_00 18:29

Yeah, we have to stop looking for a single hero to save the day and start building a comprehensive overlapping defense strategy for the brain.

SPEAKER_01 18:36

Absolutely.

SPEAKER_00 18:37

So to recap the journey we have been on today, we started with a smudged clue in a 1907 medical paper where Allois Alzheimer's first noticed lipid accumulation in brain cells. That forgotten detail, combined with our modern understanding of the ApoE4 gene, led us to massive data sets showing that common cholesterol drugs can exert a tiny but statistically real effect on cognitive decline.

SPEAKER_01 19:01

A small effect, but real.

SPEAKER_00 19:02

And thanks to the brilliant trajectory math of time saved, we know those fractional points can compound to buy a family real meaningful months together.

SPEAKER_01 19:12

Yeah, we are still left staring down a profound biological mystery as the physical damage to the brain's memory center continues completely unchecked by these medications.

SPEAKER_00 19:22

And to you listening right now, this is exactly why diving deep into these primary scientific sources is so critical. It protects you from the whiplash of internet headlines.

SPEAKER_01 19:32

It really does.

SPEAKER_00 19:32

You don't have to choose between believing statins

The Paradox That Changes The Question

SPEAKER_00 19:35

are a miracle cure for dementia or statins are totally useless. You get to hold the nuanced truth.

SPEAKER_01 19:40

Ah.

SPEAKER_00 19:40

They are a powerful, pragmatic tool with complex limitations that we are still figuring out.

SPEAKER_01 19:46

As we wrap up this analysis, I want to leave you with one final thought to ponder.

SPEAKER_00 19:49

Please do.

SPEAKER_01 19:50

If these common cardiovascular medications can successfully buy patients months of cognitive function, and yet they do so without altering the classic physical hallmarks of Alzheimer's like teltangles and hippocampal shrinkage, could it be that the progression of dementia is being driven by entirely separate whole body mechanisms? Wow. Could the real battleground for our memories not just be inside the neurons, but in the vast complex vascular system that feeds them, working in ways we are only just beginning to uncover?

SPEAKER_00 20:20

It is a brilliant question to end on. It makes you wonder if fixing the body to save the mind isn't just a metaphor after all, but the actual biological blueprint we have been searching for. It just took us a century to finally wipe the smudge off the window and look at the whole picture.